CVKD
Cadrenal Therapeutics, Inc. Common Stock NASDAQ$6.35
Mkt Cap $12.7M
52w Low $4.21
16.7% of range
52w High $17.00
50d MA $6.26
200d MA $9.66
P/E (TTM)
-1.0x
EV/EBITDA
-0.7x
P/B
4.6x
Debt/Equity
0.0x
ROE
-483.3%
P/FCF
-1.1x
RSI (14)
—
ATR (14)
—
Beta
1.55
50d MA
$6.26
200d MA
$9.66
Avg Volume
49.8K
About
Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel therapy with orphan drug indication for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | 1M% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 31, 2026 | AMC | -1.17 | -1.41 | -20.5% | 5.12 | +0.4% | -4.3% | -8.2% | -9.2% | -15.6% | -5.3% | +30.3% | — |
| Nov 10, 2025 | AMC | -1.55 | -1.31 | +15.5% | 11.76 | +0.9% | +5.0% | +4.1% | -0.9% | -1.3% | -0.5% | -5.5% | — |
| Aug 11, 2025 | AMC | -1.60 | -1.87 | -16.9% | 10.94 | +0.5% | -0.3% | +6.8% | +18.1% | +15.9% | +19.3% | +21.1% | — |
| May 8, 2025 | AMC | -1.64 | -2.09 | -27.4% | 15.50 | +3.0% | -6.8% | -13.7% | -4.6% | -8.8% | -2.3% | -3.2% | — |
| Mar 13, 2025 | AMC | -1.71 | -2.74 | -60.2% | 17.45 | +1.6% | +9.4% | +13.9% | +10.8% | +11.9% | +11.7% | -11.5% | — |
| Nov 7, 2024 | AMC | -1.83 | -2.18 | -19.1% | 16.29 | +1.2% | +8.9% | +9.8% | +8.8% | +1.7% | +1.7% | -25.8% | — |
| Aug 7, 2024 | AMC | -19.04 | -2.25 | +88.2% | 6.21 | -3.9% | +4.7% | +3.9% | +6.3% | +20.8% | +25.4% | +26.1% | — |
| May 9, 2024 | AMC | -1.05 | -1.50 | -42.9% | 7.28 | -1.1% | -5.2% | -9.3% | -9.2% | -8.7% | -11.4% | -9.1% | — |
| Mar 11, 2024 | AMC | -1.35 | -0.75 | +44.4% | 9.76 | -4.4% | -10.9% | -9.9% | -8.6% | -9.6% | -13.9% | -32.1% | — |
| Nov 9, 2023 | AMC | -1.05 | -1.05 | +0.0% | 6.60 | -3.8% | -4.1% | -6.8% | -4.7% | +11.4% | +2.6% | +13.9% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.65 | $4.50 | -3.2% | -7.1% | +4.3% | +6.9% | +2.4% | +7.3% |
| May 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $15.14 | $15.16 | +0.1% | +2.4% | +1.4% | +3.6% | +3.7% | -0.7% |
| Nov 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $17.74 | $18.00 | +1.5% | +0.8% | -0.1% | -6.7% | -6.6% | -11.7% |
| Jun 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.65 | $7.79 | +1.8% | -2.0% | -7.7% | -13.5% | -8.0% | -8.5% |
| May 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.36 | $7.20 | -2.2% | -1.1% | -6.2% | -10.3% | -10.2% | -9.6% |
| Mar 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.79 | $8.79 | +0.0% | +1.5% | +0.3% | -4.4% | -2.7% | +2.4% |
Recent Filings
8-K · 8.01
!! High
Cadrenal Therapeutics, Inc. -- 8-K 8.01: Material Event / Announcement
Cadrenal Therapeutics completed its FDA End-of-Phase 2 meeting for CAD-1005, receiving guidance on Phase 3 trial design for this heart inflammation treatment, potentially accelerating development timelines.
Apr 30
8-K · 1.01
!! High
Unknown — 8-K 1.01: Material Agreement
CVKD signed a $2.5 million material agreement, suggesting new revenue opportunities or strategic partnerships that could drive near-term growth and improve financial performance.
Apr 1
8-K
Unknown — 8-K Filing
Cadrenal Therapeutics filed an 8-K with a press release, signaling a material corporate announcement that could impact stock price; investors should review the full press release details to assess the announcement's significance.
Mar 31
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
Preclinical data supporting CAD-1005's potential efficacy in diabetes and obesity could validate Corvus's therapeutic approach and drive clinical trial advancement, offering significant upside if human trials show similar inflammatory and metabolic improvements.
Mar 12
8-K · 8.01
!! High
Cadrenal Therapeutics, Inc. -- 8-K 8.01: Material Event / Announcement
Cadrenal Therapeutics reports positive trial results for CAD-1005 in heparin-induced thrombocytopenia, potentially establishing a new surrogate endpoint through collaboration with previous sponsor Veralox Therapeutics.
Feb 24
Data updated apr 25, 2026 4:06am
· Source: massive.com